Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

The FDA should be more open and collaborative to unleash a surge in approvals of rare disease drugs, according to a report by ...

Four years after launching a remote-controlled robotic laboratory in San Diego, Eli Lilly is shipping the operation overseas.

After 25 years at Johnson & Johnson and 30 in the industry, Lucinda Warren is moving on to new pastures at Cue Biopharma as ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Medtronic is bringing on a new chief medical officer for its digital and robotics teams, who it described as one of the top ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...